Literature DB >> 23325273

Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis.

Troels M Busk1, Flemming Bendtsen, Søren Møller.   

Abstract

Refractory ascites and recurrent variceal bleeding are among the serious complications of portal hypertension and cirrhosis for which a transjugular intrahepatic portosystemic shunt (TIPS) can be used. Cirrhotic patients have varying degrees of haemodynamic derangement, mainly characterized by peripheral arterial vasodilatation, central underfilling and activation of several vasoactive systems. These changes affect the heart, the lungs and the kidneys in particular. The cardiac effects of TIPS are immediate and are related to the redirection of blood from the splanchnic circulation into the systemic circulation, resulting in worsening of the hyperdynamic circulation with increasing cardiac output and decreasing systemic vascular resistance; further, TIPS may unmask a latent diastolic dysfunction of the heart. However, the renal effects of TIPS seem to be beneficial as renal function tends to improve in patients with the hepatorenal syndrome. The clinical and haemodynamic effects of TIPS have been studied intensively and will be reviewed in the present paper. Considerable knowledge on the effects of TIPS on the pathophysiology of cirrhosis has been gained, but studies on the central haemodynamic effects are warranted to refine the already applied treatments and develop new treatment modalities.

Entities:  

Mesh:

Year:  2013        PMID: 23325273     DOI: 10.1097/MEG.0b013e32835d09fe

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.

Authors:  Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

2.  Cirrhosis-related changes in left ventricular function and correlation with the model for end-stage liver disease score.

Authors:  Xiaopeng Li; Shanshan Yu; Lu Li; Donggang Han; Shejiao Dai; Ya Gao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  Outcomes of transjugular intrahepatic portosystemic shunts for ascites.

Authors:  Zachary L Bercu; Aaron M Fischman
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 4.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

5.  Diagnosis and Management of Cirrhotic Cardiomyopathy.

Authors:  Harpreet Kaur; Madhumita Premkumar
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

6.  Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.

Authors:  Michael Praktiknjo; Jasmin Abu-Omar; Johannes Chang; Daniel Thomas; Christian Jansen; Patrick Kupczyk; Filippo Schepis; Juan Carlos Garcia-Pagan; Manuela Merli; Carsten Meyer; Christian P Strassburg; Claus C Pieper; Jonel Trebicka
Journal:  JHEP Rep       Date:  2021-03-03

7.  Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Giulia Manguso; Anthony Vignone; Manuela Merli; Cristiano Miotti; Annalisa Caputo; Carmine Dario Vizza; Roberto Badagliacca
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.